Summary
Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2 and also HER3. 
attributable, in many cases, to emergence of KRAS mutations (5), or less frequently, to HER2 amplification (6).
To circumvent both structural plasticity and the functional redundancy of the HER network, Jacobsen and colleagues undertook a dual pronged attack (see Figure   1 ): First, they simultaneously targeted EGFR, HER2 and HER3, such that evasion mechanisms were blocked. Second, because pairs of mAbs engaging mutually nonoverlapping epitopes robustly eliminate the target (7, 8) , and a similar HER2-targeting pair has been approved for treatment of mammary tumors (9), the authors employed pairs rather than single mAbs. This strategy translated to application of a mixture of six mAbs, which they denoted Pan-HER. As expected, each of the selected pairs synergistically inhibited metabolic activity of epithelial cells, in vitro, and more strongly sorted their targets for degradation than did the respective single mAbs. Ultimately, the authors tested Pan-HER on several hard-to-treat cancer models, in animals, including xenografts derived from ovary, colorectal, lung and pancreas cancer patients (PDX models). In all models, Pan-HER outperformed cetuximab and trastuzumab, and in some models the inhibitory action was not only sustained but also persisted after withdrawal of the mixture of six antibodies. 
